<code id='A4BA90AD1A'></code><style id='A4BA90AD1A'></style>
    • <acronym id='A4BA90AD1A'></acronym>
      <center id='A4BA90AD1A'><center id='A4BA90AD1A'><tfoot id='A4BA90AD1A'></tfoot></center><abbr id='A4BA90AD1A'><dir id='A4BA90AD1A'><tfoot id='A4BA90AD1A'></tfoot><noframes id='A4BA90AD1A'>

    • <optgroup id='A4BA90AD1A'><strike id='A4BA90AD1A'><sup id='A4BA90AD1A'></sup></strike><code id='A4BA90AD1A'></code></optgroup>
        1. <b id='A4BA90AD1A'><label id='A4BA90AD1A'><select id='A4BA90AD1A'><dt id='A4BA90AD1A'><span id='A4BA90AD1A'></span></dt></select></label></b><u id='A4BA90AD1A'></u>
          <i id='A4BA90AD1A'><strike id='A4BA90AD1A'><tt id='A4BA90AD1A'><pre id='A4BA90AD1A'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:92437
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          What would happen to your eyes if you looked at the solar eclipse?
          What would happen to your eyes if you looked at the solar eclipse?

          PeopleacrosstheU.S.willbeabletowatchMonday'ssolareclipse—butcanwatchingitwithoutanyeyeprotectionhurt

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

          SipaviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletter